医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taro to Announce First Quarter Results on August 9, 2018

2018年08月03日 AM02:44
このエントリーをはてなブックマークに追加


 

HAWTHORNE, N.Y.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2018, after the close of market on Thursday, August 9, 2018.

The release will be accessible on Taro’s website at www.taro.com.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005744/en/

CONTACT

Taro Pharmaceutical Industries Ltd.
Mariano A. Balaguer
VP,
CFO
914-345-9001
Mariano.Balaguer@taro.com
or
William
J. Coote

AVP, Business Finance, Treasurer and Investor Relations
914-345-9001
William.Coote@taro.com

同じカテゴリーの記事 

  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
  • Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
  • BrainChip Earns Australian Patent for Improved Spiking Neural Network
  • Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies